Brief: Allena Pharmaceuticals Reports Positive Reloxaliase Topline Results From Urirox-1 Trial And From Study 206

Allena Pharmaceuticals

07/11/2019 17:15

Nov 7 (Reuters) - Allena Pharmaceuticals Inc  ALNA.O :
    * ALLENA PHARMACEUTICALS REPORTS POSITIVE RELOXALIASE
TOPLINE
RESULTS FROM URIROX-1 TRIAL AND FROM STUDY 206
    * ALLENA PHARMA - URIROX-1 TRIAL ACHIEVES PRIMARY ENDPOINT
WITH
STATISTICALLY SIGNIFICANT REDUCTION IN URINARY OXALATE WITH
ENTERIC HYPEROXALURIA
    * ALLENA PHARMA - PHASE 2 STUDY 206 TRIAL DEMONSTRATES
SUBSTANTIAL
PLASMA OXALATE REDUCTION WITH ENTERIC HYPEROXALURIA, ADVANCED
CHRONIC KIDNEY DISEASE
    * ALLENA PHARMA - RELOXALIASE WAS WELL TOLERATED IN URIROX-1
TRIAL

Source text for Eikon:  ID:nGNX3L1tWY 
Further company coverage:  ALNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))